Upon retiring from Pfizer Inc. after a distinguished 30 year career, Jack joined Oligomerix, Inc. as a Director and Chief Commercial Officer in 2010. OLIGOMERIX is a biopharmaceutical company located in New York City focused on early stage drug discovery targeting tau protease in Alzheimer’s disease.
At Pfizer, Jack gained broad commercial leadership experience across a range of responsibilities. For eight years prior to retiring, Jack was Vice-President, Worldwide Marketing responsible for Pfizer’s Global Infectious Diseases and Respiratory Therapeutic Groups. He led successful global launches of many of Pfizer’s novel products including Spiriva, Diflucan, Vfend, and Zithromax, which generated in excess of $5B in revenue.
Two of Jack’s key contributions include the leadership of the global alliance with Boehringer-Ingelheim that launched and built Spiriva into the most prescribed medicine in the world for the treatment of COPD. He also spearheaded the development of several key philanthropic programs for Pfizer, including the Diflucan Partnership Program, which makes available Pfizer’s novel anti-fungal to patients in 62 developing countries who are suffering from life-threatening fungal infections and cannot afford to pay.
Jack’s other responsibilities included three years as Vice-President of Business Intelligence & Planning and a year as Pfizer’s Regional President of the Africa, Middle East Region. In 1997 Jack was appointed Vice President Product Development.
Linking his passion for helping the medically disadvantaged address their medical needs, Jack served on the Board of the American Lung Association of the City of New York for five years providing insight and support for novel programs addressing childhood asthma, anti-smoking campaigns and various health awareness programs.
Jack graduated from Merrimack College with a BS in Business Administration and earned an MBA from Fairleigh Dickinson University in New Jersey.